Previous 10 | Next 10 |
2023-08-28 10:05:32 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) Tech Ruled The First Half Of 2023, The Industry You Need To Watch In The Second Half XLV Vs. VHT: A Head-To-Head Healthcare ETF C...
2023-08-28 08:16:32 ET More on pre-market losers: AMC Crash Limits Turnaround Potential AMC: Bankruptcy Is Almost Certain Stocks To Watch: Spotlight On Nvidia, AMC Entertainment, Snowflake, Twilio And DICK'S Sporting Goods AMC Entertainment's APE Conversion: ...
2023-08-28 07:54:18 ET More on NovoCure NovoCure Limited: Record Losses, Falling Margins, And Downward Momentum NovoCure: Uncertain Regulatory Path And Slowing Growth NovoCure Limited ( NVCR ) Q2 2023 Earnings Call Transcript NovoCure Limited 2023 Q2 - Re...
Novocure (NASDAQ: NVCR) today announced that the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial of Tumor Treating Fields (TTFields) together with paclitaxel in patients with platinum-resistant ovarian cancer did not meet its primary endpoint of overall survival (OS) at the final analys...
2023-08-23 09:04:00 ET Summary NovoCure sells and develops devices intended to treat solid tumor cancers using physical forces related to electric fields. The firm’s sales growth ended in Q3-2020, and since then operating and net margins (LTM) have been deteriorating. Its n...
San Diego, California--(Newsfile Corp. - August 12, 2023) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of NovoCure Limited (NASDAQ: NVCR) securities between January 5, 2023 and June 5, 2023, all dates inclusive (the "Class Period") have until A...
2023-08-09 10:45:00 ET Growth stocks have been top performers in 2023 after lagging behind value and dividend stocks in 2022. And despite the signs of a slowing global economy, growth stocks are expected to maintain their momentum in the near future, thanks to the sharp pullback in this ass...
2023-08-09 05:10:00 ET When it comes to oncology therapies, most people probably think about drugs, but NovoCure (NASDAQ: NVCR) has a radically different approach. Its portable anti-cancer device is already on the market, and it appears to be a helpful add-on treatment for glioblast...
2023-08-08 16:11:00 ET Cancer-focused biotech Novocure (NASDAQ: NVCR) was the focus of an analyst upgrade on Tuesday, and the stock benefited from the move. In late-session trading that day, it was up by more than 3.3% in price, in contrast to the 0.5% slump of the bellwether S&am...
2023-08-08 14:20:40 ET More on NovoCure NovoCure: Uncertain Regulatory Path And Slowing Growth NovoCure At 5 Year Lows: Avoid Or Opportunity? NovoCure upgraded at Wedbush citing balanced risk-reward setup Why did NovoCure stock crash today? TTFields data ...
News, Short Squeeze, Breakout and More Instantly...
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three...
2024-06-13 14:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-04 10:45:03 ET Wells Fargo analyst issues NEUTRAL recommendation for NVCR on June 4, 2024 09:01AM ET. The previous analyst recommendation was Neutral. NVCR was trading at $24.055 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cur...